Effects of Doxazosin Mesylate in Patients with Benign Prostatic Hyperplasia.
- Author:
Duck Jin CHANG
1
;
Phil Ah PARK
;
Chang Yeol BYUN
;
Suck Ho YEA
;
Sung Ryong CHO
Author Information
1. Departments of Urology, Taegu Fatima Hospital, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Benign prostatic hyperplasia;
Doxazosin mesylate
- MeSH:
Adrenergic Antagonists;
Aged, 80 and over;
Doxazosin*;
Drug-Related Side Effects and Adverse Reactions;
Humans;
Prostatic Hyperplasia*;
Urination;
Urodynamics
- From:Korean Journal of Urology
1994;35(5):509-514
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The clinical effect of doxazosin mesylate, a selective long acting alpha-1 adrenergic blocker, were evaluated in 31 patients with symptomatic benign prostatic hyperplasia ranging from 49- 85 years old. All patients underwent a urodynamic evaluation and symptom score checking before enrollment into the study. The dose of doxazosin was 2mg per day. And the mean duration of treatment was 157 days. 31 patients were followed on doxazosin for 3 to 12 months with mean 7.5 months. The adverse drug reactions were observed only 1 case. The parameters used to assess the effectiveness of doxazosin included peak and mean urinary flow rates, micturition symptom scores and residual urine, and global assessment by the patient The peak and mean urinary flow rates increased by 77% and 86%, respectively. The obstructive and irritative symptom scores were improved by 51% and 41% respectively. The improvements in urinary flow rates and symptom scores were maintained for this interval. Although this preliminary experience with doxazosin is encouraging, the ultimate role of doxazosin for the long term treatment of benign prostatic hyperplasia needs further evaluation.
